The presence of elevated levels of HERV-K Env-specific T-cell proliferation, cytokine production, and HERV-K-specific cytotoxic T lymphocyte activity were identified in breast cancer and ovarian cancer patients (Wang-Johanning et al., 2008; Rycaj et al., 2015). This evidence concerns the gene ERVW-1 and ovarian carcinoma.